Published in J Cell Physiol on November 01, 2010
Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis. Blood (2013) 0.99
Activation of non-canonical TGF-β1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis. Blood Cells Mol Dis (2015) 0.79
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial. Blood Cancer J (2015) 0.77
Hematopoiesis: an evolving paradigm for stem cell biology. Cell (2008) 11.95
Myelofibrosis with myeloid metaplasia. N Engl J Med (2000) 7.04
Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. Science (2003) 3.70
Stem cell repopulation efficiency but not pool size is governed by p27(kip1). Nat Med (2000) 3.15
Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell (2008) 3.02
The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood (2009) 2.85
The major human erythroid DNA-binding protein (GF-1): primary sequence and localization of the gene to the X chromosome. Proc Natl Acad Sci U S A (1990) 2.68
p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell (2005) 2.65
Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization. Nat Med (2005) 2.63
Critical roles for Rac1 and Rac2 GTPases in B cell development and signaling. Science (2003) 2.46
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia (2007) 2.31
Chemokines in hematopoiesis. Curr Opin Hematol (2008) 2.01
In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results. Eur J Cancer (2002) 1.48
GATA-2 reinforces megakaryocyte development in the absence of GATA-1. Mol Cell Biol (2009) 1.44
Megakaryocyte-osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2. J Bone Miner Res (2003) 1.39
Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood (2008) 1.35
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells (2008) 1.30
p27Kip1 inhibits cyclin D-cyclin-dependent kinase 4 by two independent modes. Mol Cell Biol (2008) 1.19
The hypomorphic Gata1low mutation alters the proliferation/differentiation potential of the common megakaryocytic-erythroid progenitor. Blood (2006) 1.13
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res (2008) 1.11
In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer (1998) 1.09
p27Kip1 acts downstream of N-cadherin-mediated cell adhesion to promote myogenesis beyond cell cycle regulation. Mol Biol Cell (2005) 1.09
A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood (2005) 1.06
Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis. Expert Rev Hematol (2009) 1.06
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. Am J Pathol (2005) 1.05
Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res (2007) 1.04
Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation. Cell Death Differ (2006) 1.04
Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. Exp Hematol (2008) 1.02
Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma. Br J Cancer (2008) 1.00
New and old treatment modalities in primary myelofibrosis. Cancer J (2007) 0.99
Antiangiogenic activity of aplidine, a new agent of marine origin. Br J Cancer (2004) 0.97
VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia. Ann Oncol (2005) 0.96
Levels of p27(kip1) determine Aplidin sensitivity. Mol Cancer Ther (2007) 0.94
Variegation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds. Blood (2005) 0.91
Expression of bone morphogenetic proteins and their receptors in the bone marrow megakaryocytes of GATA-1(low) mice: a possible role in osteosclerosis. J Histochem Cytochem (2007) 0.91
Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1/c-Jun NH2-terminal kinase activation in human melanoma cells. J Pharmacol Exp Ther (2007) 0.90
The mechanism of action of plitidepsin. Curr Opin Investig Drugs (2009) 0.90
Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Cancer Chemother Pharmacol (2005) 0.89
In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells. Exp Hematol (2003) 0.88
Gata1 expression driven by the alternative HS2 enhancer in the spleen rescues the hematopoietic failure induced by the hypomorphic Gata1low mutation. Blood (2009) 0.87
Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma. Clin Cancer Res (2005) 0.86
The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. Clin Adv Hematol Oncol (2009) 0.84
p27KIP1 and GATA-1 are potential downstream molecules in activin A-induced differentiation and apoptosis pathways in CML cells. Oncol Rep (2006) 0.81
Evidence for organ-specific stem cell microenvironments. J Cell Physiol (2010) 0.81
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med (2012) 10.07
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood (2008) 7.73
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol (2011) 3.83
Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood (2002) 3.06
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood (2013) 2.77
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood (2009) 2.77
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood (2013) 2.60
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood (2007) 2.53
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica (2008) 2.46
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood (2007) 2.41
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood (2009) 2.11
The homeodomain protein Meis1 is essential for definitive hematopoiesis and vascular patterning in the mouse embryo. Dev Biol (2005) 2.10
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood (2008) 2.09
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood (2011) 1.93
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol (2011) 1.88
Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin (2009) 1.87
Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J Clin Oncol (2005) 1.80
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res (2005) 1.80
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood (2009) 1.78
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood (2012) 1.77
In vitro mass production of human erythroid cells from the blood of normal donors and of thalassemic patients. Blood Cells Mol Dis (2002) 1.70
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol (2014) 1.65
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood (2011) 1.63
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol (2012) 1.58
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood (2011) 1.56
Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol (2007) 1.52
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood (2012) 1.52
Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows. Haematologica (2007) 1.51
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leuk Res (2011) 1.50
Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN. Exp Hematol (2009) 1.48
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood (2012) 1.48
EZH2 mutational status predicts poor survival in myelofibrosis. Blood (2011) 1.45
Therapeutic approaches in myelofibrosis. Expert Opin Pharmacother (2011) 1.43
Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations. Leuk Lymphoma (2014) 1.41
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). Stem Cells (2006) 1.41
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol (2005) 1.41
Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol (2008) 1.40
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev (2009) 1.39
Thrombosis in primary myelofibrosis: incidence and risk factors. Blood (2009) 1.37
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood (2011) 1.34
Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood (2008) 1.33
Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther (2005) 1.32
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood (2013) 1.30
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells (2008) 1.30
Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol Pharmacol (2005) 1.30
A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol (2010) 1.29
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood (2011) 1.26
The haematocrit and platelet target in polycythemia vera. Br J Haematol (2006) 1.25
The use of India ink in tissue-simulating phantoms. Opt Express (2010) 1.23
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica (2010) 1.22
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer (2014) 1.22
Long-term repopulating ability of telomerase-deficient murine hematopoietic stem cells. Blood (2002) 1.22
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica (2008) 1.21
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood (2013) 1.19
Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol (2012) 1.19
Masked polycythemia vera (mPV): results of an international study. Am J Hematol (2013) 1.19
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol (2009) 1.18
Intralipid: towards a diffusive reference standard for optical tissue phantoms. Phys Med Biol (2010) 1.17
JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol (2009) 1.16
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood (2010) 1.16
Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice. Blood (2004) 1.15
MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exp Hematol (2007) 1.14